Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on a Special General Meeting of shareholders held by Akari Therapeutics Plc on March 2, 2026. The filing details the voting results for several ordinary resolutions submitted to shareholders to comply with Nasdaq Listing Rules regarding the exercisability of various warrants issued in recent financing transactions.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved five ordinary resolutions related to the exercisability of warrants issued in late 2025. The total number of ordinary shares entitled to vote was 91,567,009,533. All proposals received overwhelming support:
- Resolution 1: Approval of Series G Warrants (10,043,774 ADSs) and Placement Agent Warrants (504,300 ADSs) from offerings closed in December 2025 and January 2026. Votes: 40,370,290,401 For; 307,764,000 Against.
- Resolution 2: Approval of Pre-Funded Warrants and Series G Warrants (2,563,713 ADSs each) from a private placement closed December 23, 2025. Votes: 40,371,532,401 For; 307,920,000 Against.
- Resolution 3: Approval of Pre-Funded Warrants and Series G Warrants (2,563,713 ADSs each) from the same December 23, 2025 private placement under a different Nasdaq rule. Votes: 40,370,370,401 For; 308,000,000 Against.
- Resolution 4: Approval of Pre-Funded Warrants and Note Exchange Warrants (4,673,963 ADSs each) from a note exchange closed December 17, 2025. Votes: 40,371,562,401 For; 308,002,000 Against.
- Resolution 5: Approval of Pre-Funded Warrants and Note Exchange Warrants (9,502,703 ADSs each) from the same December 17, 2025 note exchange. Votes: 40,444,976,401 For; 241,588,000 Against.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The primary purpose is to disclose the final voting results required by Nasdaq Listing Rules 5635(c) and 5635(d).
Investor Verification Checklist
- Verify the total number of ordinary shares outstanding and the significant dilution potential from the approved warrant exercises.
- Review the definitive proxy statement on Schedule 14A filed on February 2, 2026, for detailed terms of the warrant issuances.
- Confirm the closing dates and terms of the registered direct offering (December 17, 2025), concurrent private placement (January 20, 2026), and note exchange (December 17, 2025).
- Monitor future filings for the actual exercise of these warrants and the resulting issuance of ADSs and ordinary shares.